We invest in a healthier future

Life Sciences

Taking a medical innovation from the conceptual stage to an approved, clinically and market relevant product takes skill, time and money.

Sarsia's highly experienced team of engineers, technologists, biologists and pharmacologists identify and support, through active ownership, innovative research-based companies working to develop and bring to market products with a high medical need.

Life Science prospects are "born global". With world-class research, investing in the Norwegian Life Science sector is an attractive proposition. Sarsia is Norway’s leading early-stage Life Science investment firm. We combine our technological knowledge and solid understanding of the market, with a vibrant international network.

Examples of investment areas:

  • Biomedicine and biotech
  • Medical instrumentation and technology platforms
  • Diagnostic tools and biotechnological products
  • Marine biology and technology related to aquaculture
pipette dripping liquid into test tubes

Latest news about Life Sciences

  • Mon Jan 02 2023

    Coegin Pharma raises 25 mSEK

    Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new

    Read full article
  • Fri Dec 16 2022

    Rallybio publishes promising results with technology aquired from Prophylix Pharma

    American biotech company Rallybio publishes proof-of-concept data from animal studies with technolog

    Read full article
  • Tue Dec 06 2022

    Nykode Therapeutics announces clinical collaboration with MSD

    Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination Wit

    Read full article

Other investment areas

  • Technology, Energy and Sustainability

    We search for technologies and founders capable of accelerating the green transition and of building sustainable companies for the future.

    Visit page